Trials / Completed
CompletedNCT05068440
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib in Patients With CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial was to evaluate whether zanubrutinib can effectively treat adults with CD79B-mutant relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Participants received zanubrutinib as monotherapy, underwent regular disease assessments to evaluate treatment response, and were monitored for safety and side effects throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | Administered orally as capsules at a dose of 160 mg twice daily on a continuous dosing schedule. |
Timeline
- Start date
- 2021-08-11
- Primary completion
- 2025-03-31
- Completion
- 2025-03-31
- First posted
- 2021-10-05
- Last updated
- 2026-03-25
- Results posted
- 2026-03-25
Locations
25 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05068440. Inclusion in this directory is not an endorsement.